Bill's Feed
Apr 8, 2015

Generic drugmaker Mylan offers 19 billion pounds for Perrigo

By Bill Berkrot

(Reuters) – Generic drugmaker Mylan NV (MYL.O: Quote, Profile, Research) said on Wednesday it has offered to buy Perrigo Co Plc (PRGO.N: Quote, Profile, Research) for about $29 billion (19.43 billion pounds) in cash and stock in a move that would significantly beef up Mylan’s offerings of over-the-counter consumer products.

Mylan said it proposed to acquire the Ireland-based company for $205 per share, representing more than a 25 percent premium over Perrigo’s April 3 closing price, the last trading day prior to the Mylan proposal.

Apr 8, 2015

Generic drugmaker Mylan offers $29 billion for Perrigo

By Bill Berkrot

(Reuters) – Generic drugmaker Mylan NV (MYL.O: Quote, Profile, Research, Stock Buzz) said on Wednesday it has offered to buy Perrigo Co Plc (PRGO.N: Quote, Profile, Research, Stock Buzz) for about $29 billion in cash and stock in a move that would significantly beef up Mylan’s offerings of over-the-counter consumer products.

Mylan said it proposed to acquire the Ireland-based company for $205 per share, representing more than a 25 percent premium over Perrigo’s April 3 closing price, the last trading day prior to the Mylan proposal.

Mar 26, 2015

Genfit to conduct large liver drug trial despite setback

By Bill Berkrot and Ransdell Pierson

(Reuters) – French drugmaker Genfit SA said on Thursday it will begin a late stage trial later this year of its lead treatment for a liver-destroying condition, saying it failed a midstage trial in part due to its inclusion of many patients with a mild form of the disease.

The company said had it excluded data from those patients with the mildest form of the disease known as NASH (non-alcoholic steatohepatitis) its drug, called GFT505, would have been deemed effective in reversing the condition. Company officials said Genfit would likely include only more seriously ill patients in its planned Phase III trials which will test 1,500 to 2,000 patients.

Mar 23, 2015

Exclusive: Biogen shortens name, expands ambitions in Alzheimer’s, ALS

NEW YORK (Reuters) – Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

The Massachusetts-based company, which made headlines last week when it announced better-than-expected clinical trial results for its experimental Alzheimer’s drug, aducanumab, said that it will drop Idec from its name as of Monday and adopt a new logo. The company merged with Idec Pharmaceuticals more than a decade ago.

Mar 20, 2015

Biogen’s Alzheimer’s drug slows mental decline in early study

March 20 (Reuters) – An experimental drug from Biogen Idec
became the first Alzheimer’s treatment to significantly slow
cognitive decline and reduce what is believed to be
brain-destroying plaque in patients with early and mild forms of
the disease, according to a small study likely to reignite hopes
of a treatment.

Alzheimer’s is expected to strike as many as 75 million
people worldwide by 2030 without effective treatments, likely
costing billions of dollars year in care. A successful treatment
would pay some of the richest rewards in medicine.

Mar 17, 2015

Corrected – New market for liver disease spawns race for better testing

NEW YORK (Reuters) – As drugmakers develop new medicines to battle a liver disease epidemic, they have created an urgent need for better diagnostics to select patients for treatment and assess their drugs’ effectiveness.

About 30 percent of people in the U.S. now suffer from fatty liver diseases, such as NASH (nonalcoholic steatohepatitis), fuelled by obesity, diabetes and over-indulgent lifestyles, according to the American Liver Foundation. Without treatment, sufferers can develop advanced damage, including the scarring known as fibrosis; cirrhosis, which destroys liver function; and even cancer.

Mar 15, 2015

Low mortality, stroke seen with newest Edwards TAVR system -study

March 15 (Reuters) – Researchers on Sunday presented trial
data showing very low mortality and stroke rates using the third
generation version of Edwards Lifesciences Corp’s
non-invasive heart valve replacement system that could help
support its U.S. approval.

Data compiled 30 days after the procedure showed a 2.2
percent mortality rate in high risk patients and a 1.1 percent
death rate among intermediate risk patients whose diseased heart
valves were replaced using the Edwards Sapien 3 transcatheter
aortic valve replacement (TAVR) system.

Mar 15, 2015

Medtronic valve replacement tops surgery after 2 years -study

March 15 (Reuters) – Patients treated with Medtronic Plc’s
CoreValve non-invasive heart valve replacement system
fared better two years after the procedure than those who
underwent surgical valve replacement, according to data from a
study presented on Sunday.

The data not only showed that results seen at one year were
sustained a year later, but that there were greater differences
favoring Medtronic’s transcatheter aortic valve replacement
(TAVR) compared with open heart surgery.

Mar 15, 2015

Insight – New market for liver disease spawns race for better testing

NEW YORK (Reuters) – As drugmakers develop new medicines to battle a liver disease epidemic, they have created an urgent need for better diagnostics to select patients for treatment and assess their drugs’ effectiveness.

About 30 percent of people in the U.S. now suffer from fatty liver diseases, such as NASH (non-alcoholic steatohepatitis), fuelled by obesity, diabetes and over-indulgent lifestyles, according to the American Liver Foundation. Without treatment, sufferers can develop advanced damage, including the scarring known as fibrosis; cirrhosis, which destroys liver function; and even cancer.

Mar 15, 2015

New market for liver disease spawns race for better testing

NEW YORK, March 15 (Reuters) – As drugmakers develop new
medicines to battle a liver disease epidemic, they have created
an urgent need for better diagnostics to select patients for
treatment and assess their drugs’ effectiveness.

About 30 percent of people in the U.S. now suffer from fatty
liver diseases, such as NASH (nonalcoholic steatohepatitis),
fueled by obesity, diabetes and over-indulgent lifestyles,
according to the American Liver Foundation. Without treatment,
sufferers can develop advanced damage, including the scarring
known as fibrosis; cirrhosis, which destroys liver function; and
even cancer.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill